BCDABioCardia, Inc.

Nasdaq biocardia.com


$ 2.65 $ -0.23 (-9.2 %)    

Thursday, 05-Sep-2024 12:42:12 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 2.27
$ 2.52 x 100
-- x --
-- - --
$ 1.96 - $ 23.25
275,554
na
4.82M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-27-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-29-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-30-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 04-09-2020 12-31-2019 10-K
20 11-19-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 04-02-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-11-2017 03-31-2017 10-Q
31 03-30-2017 12-31-2016 10-K
32 10-17-2016 09-30-2016 10-Q
33 08-02-2016 06-30-2016 10-Q
34 05-03-2016 03-31-2016 10-Q
35 03-25-2016 12-31-2015 10-K
36 10-29-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-24-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-biocardia-bcda-stock-is-falling-today

BioCardia shares are trading lower by 12% during Friday's session. The company announced the pricing of an upsized public o...

 why-biocardia-bcda-stock-is-up-95-today

BioCardia shares are trading higher by 95% during Thursday's session. The FDA cleared the company to market its Morph DNA S...

Core News & Articles

BCDA: 162% | BioCardia shares are trading higher after FDA cleared the company to market its Morph DNA Steerable Introducer pro...

 hc-wainwright--co-reiterates-buy-on-biocardia-maintains-25-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.

 hc-wainwright--co-maintains-buy-on-biocardia-adjusts-price-target-to-25-1-15-reverse-stock-split

HC Wainwright & Co. analyst Joseph Pantginis maintains BioCardia (NASDAQ:BCDA) with a Buy, adjusts target to $25 from $4 (1...

 biocardia-q2-2024-gaap-eps-088-sales-3000k-miss-50000k-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.88) per share. The company reported quarterly sales of $3.000 thousan...

 biocardia-says-submitted-510k-for-approval-of-its-patented-morph-dna-steerable-introducer-sheath

This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, g...

 hc-wainwright--co-reiterates-buy-on-biocardia-maintains-4-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $4 price target.

 biocardia-secures-new-patent-for-innovative-heart-procedure-technology

 BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular...

 biocardia-has-been-granted-us-patent-number-12036371-titled-method-of-accessing-the-left-atrium-with-a-multi-directional-steerable-catheter

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036371).pn

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION